Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind study of CCX140-B in type 2 diabetes mellitus
2009-016051-22Phase 2Completed
- Sponsor
- ChemoCentryx
- Start
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ilacirnon in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by ChemoCentryx. Primary endpoint: Incidence of adverse events. Started Nov 2009; status: completed.
02
Drugs
ilacirnon
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2009-016051-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016051-22.